The Last Mamluk Princess, Her Endowment, and Her Family History
نویسندگان
چکیده
منابع مشابه
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer, and non-small cell lung cancer (NSCLC). Despite the clinical success of cetuximab, many patients do not respond to cetuximab. Furthermore, virtually all patients who do initially respond become refractory, highlighting both intrinsic and acquired r...
متن کاملExpression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers.
A significant number of HER-2 amplified breast cancers is effectively treated by trastuzumab and further shows receptor-enhanced chemosensitivity. Recent studies have postulated transactivation of HER-2 also in tumors expressing phosphorylated/activated HER-2 (pHER-2) and of the HER-3/HER-4 ligand heregulin (HRG), independent of HER-2 amplification. As a consequence, a subset of tumors without ...
متن کاملThe ErbB/HER family of protein-tyrosine kinases and cancer.
The human epidermal growth factor receptor (EGFR) family consists of four members that belong to the ErbB lineage of proteins (ErbB1-4). These receptors consist of a glycosylated extracellular domain, a single hydrophobic transmembrane segment, and an intracellular portion with a juxtamembrane segment, a protein kinase domain, and a carboxyterminal tail. Seven ligands bind to EGFR including epi...
متن کاملHER SOA - History, Environment and Rating information enabled SOA
The explosion in popularity of SOA has led to the development of applications in ‘mash-up’ format with little regard to client’s non-functional requirements. These ‘mash-ups’ or web application hybrids are certainly a potential driving factor in the increased use of SOA based applications. This position paper outlines the need for the inclusion of a client’s non-functional requirements in the d...
متن کاملTargeting the HER/EGFR/ErbB family to prevent breast cancer.
Preventing breast cancer is possible with selective estrogen receptor (ER) modulators and aromatase inhibitors, which reduce the risk of invasive disease by up to 65% (up to 73% for ER-positive and no effect for ER-negative cancer) and the risk of preinvasive disease [ductal carcinoma in situ (DCIS)] by up to 50%. Clearly, approaches for preventing ER-negative, and increased prevention of ER-po...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Orient
سال: 2019
ISSN: 0473-3851,1884-1392
DOI: 10.5356/orient.54.55